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ABSTRACT: The diterpenoid ester ingenol mebutate (IngMeb) is the
active ingredient in the topical drug Picato, a ﬁrst-in-class treatment for
the precancerous skin condition actinic keratosis. IngMeb is proposed to
exert its therapeutic eﬀects through a dual mode of action involving (i)
induction of cell death that is associated with mitochondrial dysfunction
followed by (ii) stimulation of a local inﬂammatory response, at least
partially driven by protein kinase C (PKC) activation. Although this
therapeutic model has been well characterized, the complete set of
molecular targets responsible for mediating IngMeb activity remains ill-
deﬁned. Here, we have synthesized a photoreactive, clickable analogue of
IngMeb and used this probe in quantitative proteomic experiments to
map several protein targets of IngMeb in human cancer cell lines and
primary human keratinocytes. Prominent among these targets was the
mitochondrial carnitine-acylcarnitine translocase SLC25A20, which we
show is inhibited in cells by IngMeb and the more stable analogue ingenol disoxate (IngDsx), but not by the canonical PKC
agonist 12-O-tetradecanoylphorbol-13-acetate (TPA). SLC25A20 blockade by IngMeb and IngDsx leads to a buildup of cellular
acylcarnitines and blockade of fatty acid oxidation (FAO), pointing to a possible mechanism for IngMeb-mediated perturbations
in mitochondrial function.
■ INTRODUCTION
Natural products and natural product-inspired compounds
make up roughly 40% of all drugs approved for clinical use,
including a substantial fraction of anticancer drugs.1,2 Natural
products, likely due to a combination of their sophisticated
chemical structures and diverse biological activities reﬁned by
millions of years of evolution, have been found to access unique
biological target space when compared to synthetic libraries of
small molecules, underscoring the importance of natural
products for the discovery of new chemical probes and
therapeutic agents.3−7
Despite the venerable role played by natural products in drug
discovery, the relative number of natural product-based
therapeutics has been on a steady decline over the past several
decades.8 This change has been attributed, in part, to barriers
associated with the isolation and screening of natural products,
as well as to challenges stemming from their structural
complexity that impact analytical characterization and access
to synthetic material and derivatives.9,10 Such problems are now
being addressed by technological advances in natural product
isolation and screening strategies9,11 combined with modern
synthetic methods that emphasize eﬃcient, scalable production
of natural products with interceptable intermediates and
opportunity for late-stage chemical derivatization.
Synthetic advances also have the potential to address another
persistent bottleneck in the characterization of natural products,
namely, elucidation of biological targets for these compounds.
By generating derivatives of natural products with, for instance,
aﬃnity handles, as well as structurally related, inactive
analogues, organic synthesis can provide key chemical probes
for enriching and identifying proteins that interact with natural
products in biological systems. There are many compelling
examples where the synthesis of probe derivatives proved
critical for elucidating the mechanism of action of natural
products,12−18 although success in this area still depends on
sites and routes for chemical derivatization, which may not be
readily available for some natural products.
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Natural products from the extracts of Euphorbia peplus have
been used to treat cancer for centuries.19,20 Ingenol mebutate
(IngMeb, 1), an esteriﬁed version of the parent diterpenoid
ingenol (2) and a bioactive component of the Euphorbia peplus
extract, was approved by the FDA in 2012 for the treatment of
actinic keratosis (AK).21,22 AK is a precancerous skin condition
that, if left untreated, can develop into squamous cell carcinoma
(SCC).23 IngMeb is thought to exert anticancer activity
through a complex mechanism involving cellular necrosis
followed by a localized inﬂammatory immune response.24−26
Like structurally related phorbol esters, IngMeb is a potent
agonist of protein kinase C (PKC), and this property is
proposed to induce cytokine release27,28 followed by immune
cell recruitment, cutaneous inﬁltration, and immune-mediated
clearance of residual tumor cells.29,30 However, at higher
concentrations similar to those used in topical applications,
IngMeb disrupts mitochondrial structure and function and
produces necrotic cell death in both cell-based and in vivo
models.30,31 Although PKCs are established molecular targets
of IngMeb, additional proteins are likely involved in the cellular
mechanism of action of this drug. Consistent with this
hypothesis, IngMeb, but not other PKC agonists, such as the
phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA),
blocked the growth of subcutaneous tumors in mouse
models.32 The identiﬁcation of additional protein targets for
IngMeb that may be involved in the mode of action of the drug
thus represents an important objective.
Herein, we report the development of a photoreactive,
clickable ingenol-based probe and its use to identify IngMeb-
binding proteins in human cancer cells and primary
keratinocytes using quantitative mass spectrometry (MS)-
based proteomics. Crucial to the development of these
chemical probes was an understanding of the SAR for IngMeb’s
biological activities, as well as eﬃcient synthetic access to
IngMeb triazole derivatives, enabling the development of a
“fully functionalized” probe. Prominent among several protein
targets of IngMeb identiﬁed in human cells was the
mitochondrial carnitine/acylcarnitine carrier protein
SLC25A20. Functional studies revealed that IngMeb blocks
SLC25A20 activity in cells, leading to deregulated acylcarnitine
metabolism and impairment of mitochondrial fatty acid
oxidation. Similar eﬀects were produced by a clinically relevant
analogue IngDsx, but not by TPA, therefore suggesting a
common PKC-independent mode of action by which IngMeb
and IngDsx perturb mitochondrial metabolism in human cells.
■ RESULTS AND DISCUSSION
Design and Synthesis of a Fully Functionalized
IngMeb Probe. We initially set out to identify a site on
IngMeb for installation of two functional groups: (1) a dialkyl
Figure 1. Structure−activity relationship studies and development of a fully functionalized ingenol-based probe. (A) Six-step synthesis of “azido-
ingenol” (6) leveraging an intermediate from our ingenol total synthesis. (B) Gram-scale synthesis of azido-ingenol via a four-step semisynthetic
route starting from ingenol. (C) Synthesis of ingenol-triazole analogues via CuACC along with associated biological activities. (D) Structures of a
triazole-based fully functionalized probe utilizing a diazirine photoreactive group (Ing-DAyne, 9) with corresponding biological activities. Human
protein kinase C (PKC) delta isoform activity was derived from measuring phosphorylation of PKC substrate peptide using 33P-ATP. Cytokine (IL-
8) induction activity was measured in primary human keratinocytes (HeKa) via sandwich ELISA. The ability of compounds to induce an oxidative
burst was performed in primary polymorphonuclear leukocytes (PMNs) using the superoxide indicator hydroethidine. Acute cancer cell cytotoxicity
(CC50) was determined after treatment of HeLa cells with compounds and subsequent measurement of mitochondrial activity with a resazurin-based
dye as a surrogate for cell viability. Further details can be found in the Supporting Information.
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diazirine33−40 photoreactive group for UV light-induced
covalent trapping of proteins that bind IngMeb in cells; and
(2) an alkyne group for conjugation to azide reporter tags (e.g.,
ﬂuorophores, biotin) via copper catalyzed azide−alkyne
cycoloaddition (CuAAC)41 for visualization and identiﬁcation
of IngMeb-binding proteins. We refer to such probes bearing
both photoreactive and clickable groups as “fully function-
alized” for enablement of the chemical proteomic discovery of
small-molecule-interacting proteins in human cells.
Previous SAR studies demonstrated that ingenol itself is
pharmacologically inactive42,43 and the methylation of C5- or
C20-hydroxyl groups of IngMeb also eliminates biological
activity.44 In addition, simultaneous removal of the C18/C19
methyl groups and dimethylcyclopropane moiety resulted in
substantial loss in activity.45,46 Recent studies have further
revealed that IngMeb activity requires hydroxyl groups at the
C4 and C5 positions and is maintained with various esters at
the C3 position.44,47 The 4-, 5-, and 20-hydroxyl groups,
however, also form a framework for acyl migration of the ester,
leading to subsequent loss in IngMeb potency.44 Based on
these observations, we pursued installation of a photoreactive,
clickable tag at the C3 position through coupling chemistry that
would not suﬀer from the stability issues associated with ester
group migration. Eying CuAAC chemistry as an attractive
potential solution, we developed two routes for the synthesis of
azido ingenol (6), a product that was then poised for late-stage
attachment of alkyne substituents to create analogues with
triazoles as a stable bioisotere for the ester linkage in IngMeb.
Our initial route leveraged one of the key intermediates
(compound 3) from our 14-step total synthesis of ingenol
Figure 2. Gel-based proﬁling of a fully functionalized ingenol probe in the human cancer cell line HSC-5. (A) Experimental workﬂow to visualize
Ing-DAyne probe−protein interactions in cells by SDS−PAGE coupled with in-gel ﬂuorescence scanning. (B, C) Ing-DAyne−protein interactions in
cells. HSC-5 cells were treated with Ing-DAyne (10 μM) for 30 min in situ, followed by photo-cross-linking, separation of soluble and membrane
fractions, and analysis. (B) Ing-DAyne (9) shows UV- and concentration-dependent labeling of protein targets. (C) Excess IngMeb, but not ingenol,
blocks Ing-DAyne probe labeling of several proteins in HSC-5 cells (marked with red arrows).
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(Figure 1A).48 Mesylation of 3 and subsequent treatment with
TBACl and LiN3 aﬀorded azide 4, which displayed the desired
stereochemistry at C3. We found that TBS deprotection was
best achieved using TASF. Elimination of the alcohol at C7
followed by allylic oxidation at C20 and concomitant cleavage
of the carbonate using previously developed conditions48
provided crystalline azido-ingenol (6), for which we obtained
a crystal structure that unambiguously conﬁrmed the desired
Figure 3. MS-based proﬁling with a fully functionalized ingenol probe in human cells. (A) Experimental workﬂow to identify proteins that interact
with Ing-DAyne and IngMeb in cells by quantitative MS-based proteomics. (B) Representative competition plots showing proteins for which
enrichment by the Ing-DAyne probe (10 μM) was substantially blocked (>3-fold, red dotted line) by IngMeb (100 μM) in the indicated human
cells. (C) Heatmap of high-occupancy protein targets of IngMeb (with comparison to ingenol). (D) Representative MS1 chromatograms of
SLC25A20 tryptic peptides from Ing-DAyne enrichment and IngMeb competition experiments in corresponding cell types. (E) Concentration-
dependent blockade of Ing-DAyne labeling of recombinantly expressed SLC25A20, SCCPDH, PON2, and NUCB1 in HEK293T cells by IngMeb,
but not ingenol.
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stereochemistry of the azide at C3. With 6 in hand, we were
able to access the ﬁrst triazole analogues using CuAAC
chemistry. In order to provide a more scalable and robust
approach to 6, we also developed an orthogonal semisynthesis
of azido-ingenol that started from ingenol itself (Figure 1B).
This semisynthetic route commenced with selective protection
of the C5,C20-diol as the corresponding acetonide,49 followed
by mesylation of the C3 alcohol. Notably, treatment of the
crude mesylate with sodium azide in DMF aﬀorded azide 8
with retention of the desired stereochemistry. All three steps
could be run on decagram scales without any issues. Final
deprotection of the acetonide under acidic conditions aﬀorded
azido ingenol 6. Following this semisynthetic approach, more
than 1 g of azido-ingenol could be readily prepared.
With azido-ingenol (6) in hand, we generated an alkynylated
dialkyl diazirine fully functionalized probeIng-DAyne, 9via
CuAAC chemistry with the corresponding diazirine diyne S4
(Figures 1C and 1D). We next examined the activity of the Ing-
DAyne probe in previously described assays that include in vitro
activation of recombinant PKCδ, stimulation of IL-8 release in
human primary keratinocytes, and induction of oxidative burst
in human polymorphonuclear leukocytes (PMNs, i.e., neu-
trophils).42 The Ing-DAyne probe showed ∼10−100-fold
reductions in biological activity compared to IngMb, but still
maintained submicromolar potency in both in vitro and cell-
based assays (Figure 1D), prompting us to move forward with
the Ing-DAyne probe to identify cellular targets of IngMeb.
Gel-Based Proﬁling of Protein Targets of IngMeb in
Human Cells. We initially assessed the protein-interaction
proﬁle of the Ing-DAyne probe by gel-based analysis of treated
cells (Figure 2A). The human squamous carcinoma cell line
HSC-5 was treated with Ing-DAyne (30 min), followed by
exposure to UV light (10 min, 4 °C), cell lysis, coupling to
tetramethylrhodamine (TAMRA)-azide via CuAAC chemistry,
separation into soluble and particulate fractions, SDS−PAGE,
and visualization of probe-captured proteins by in-gel
ﬂuorescence scanning. The Ing-DAyne probe showed sub-
stantial concentration-dependent labeling of proteins in both
the soluble and particulate fractions of HSC5 cells, with little to
no protein labeling in control cells not exposed to UV
irradiation (Figure 2B). Treatment of HSC-5 cells with excess
IngMeb blocked Ing-DAyne labeling of a subset of protein
targets in a concentration-dependent manner (Figure 2C). The
biologically inactive but structurally related analogue ingenol
(2) was less eﬀective at disrupting Ing-DAyne−protein
interactions in HSC-5 cells (Figure 2C). These results
prompted us to proceed forward with using the Ing-DAyne
probe in quantitative MS-based proteomic experiments.
Mass Spectrometry-Based Proﬁling of Protein Targets
of IngMeb in Human Cells. We pursued IngMeb-binding
proteins using two types of quantitative mass spectrometry
(MS)-based proteomic experiments: (1) identiﬁcation of
proteins that were enriched by the Ing-DAyne probe from
human cells in a UV light-dependent manner and (2)
identiﬁcation of proteins for which Ing-DAyne enrichment
was competitively blocked by 10× IngMeb, but not 10×
biologically inactive ingenol. We quantiﬁed proteins in each
chemical proteomic experiment by isotopic labeling, either
SILAC (stable isotope labeling with amino acids in cell
culture)50 for human cancer cell lines (HSC-5 and HeLa cells)
or an isotopic reductive dimethylation (ReDiMe)51,52 labeling
method for primary human keratinocytes (Figure 3A). Proteins
that were enriched in a UV-dependent manner (UV/no-UV
ratio >5) and competed by 10× IngMeb (DMSO/IngMeb ratio
>3), but not ingenol (DMSO/ingenol ratio <2), were
considered as potential targets relevant to the biological activity
of IngMeb (Figure 3B).
Isotopically light cells were treated with Ing-DAyne (10 μM,
30 min) followed by UV irradiation and compared to
isotopically heavy cells also treated with Ing-DAyne, but not
exposed to UV light. Following the protocol outline in Figure
3A, we identiﬁed 57, 261, and 47 proteins that were
substantially enriched (>5-fold) in a UV-dependent manner
by Ing-DAyne in HSC-5, HeLa, and keratinocyte cells,
respectively (Figures S1A−S1C) with a total of 27 Ing-
DAyne-enriched proteins that were shared across the three cell
types (Table S1). We next performed competition experiments,
where both heavy and light cells were treated with the Ing-
DAyne probe (10 μM) along with excess competitor
compound (10× IngMeb (Figure 3B) or ingenol (2, Figure
S1D); heavy) or DMSO (light), respectively. These competi-
tion experiments identiﬁed 28 high-occupancy protein targets
of IngMeb (light/heavy ratios >3) across HSC-5, HeLa, and
keratinocyte cells (Figure 3B and Table S1) with several targets
observed in all three cell types (Figure 3C,D and Table S1).
Most of these proteins did not interact with ingenol (Figure
3C), which instead competitively blocked Ing-DAyne labeling
of a mostly distinct subset of proteins in human cells (Figure
S1D). We also performed an additional competition study in
HSC-5 cells with a biologically active analogue of IngMeb
ingenol disoxate (10, IngDsx, Figure S2A)that shows
enhanced chemical stability and is currently in phase 3 clinical
development.42 We observed that the majority of high-
occupancy protein targets for IngMeb were also targets of
IngDsx (Figure S2B, Table S1), which tended to show higher
competition ratios for these shared targets.
Curiously, we did not identify members of the protein kinase
C (PKC) family as IngMeb targets in our chemical proteomic
experiments, despite Ing-DAyne showing submicromolar
agonistic activity in PKC-δ functional assays (Figure 1D). We
hypothesized that the lack of PKC enrichment could be due to
low expression of PKC-δ in the cell lines examined53 and/or
poor capture eﬃciency of this protein by the Ing-DAyne probe.
In support of the latter possibility, we recombinantly expressed
PKC-δ in HEK293T cells and failed to observe the labeling of
this protein with the Ing-DAyne probe (Figure S3). These data
underscore one of the challenges with retroactively introducing
photoreactive groups into biologically active small molecules,
namely, that, by placing the photoreactive group in a position
that does not perturb a functional protein interaction, the
photoreactive group may, in some cases, exhibit minimal
physical interactions with the protein itself and correspondingly
poor UV light induced labeling of the protein. Regardless, our
discovery of several other IngMeb-binding proteins suggested
that some of these targets may be relevant to the PKC-
independent biological activities of IngMeb. We therefore set
out to conﬁrm and further characterize some of these targets.
Conﬁrmation of IngMeb Targets Identiﬁed by
Chemical Proteomics. We veriﬁed a representative subset
of high-occupancy IngMeb targets by recombinant expression
in HEK293T cells. The cDNAs for solute carrier family 25
member 20 (SLC25A20), paraoxonase 2 (PON2), nucleobin-
din-1 (NUCB1), and saccharopine dehydrogenase-like oxidor-
eductase (SCCPDH) were transfected into HEK293T cells,
and these cells were then treated with Ing-DAyne (10 μM) and
increasing concentrations of IngMeb (1), ingenol (2), or
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DMSO for 30 min, followed by UV cross-linking, lysis,
conjugation to TAMRA-N3, and analysis by gel-based proﬁling.
Each protein showed strong labeling by Ing-DAyne compared
to mock-transfected control cells, and these labeling signals
were blocked in a concentration-dependent manner by IngMeb,
but not ingenol (Figure 3E).
IngMeb and IngDsx Inhibit the Activity of SLC25A20
in Human Cells. The necrotic cell death induced by IngMeb
in human keratinocyte, HSC-5, and HeLa cells correlates with
rupture of the mitochondrial network and parallel cytosolic
calcium release, suggesting a mechanism that involves
organellar dysfunction.31,54 We noted that over half (14) of
the high-occupancy IngMeb targets identiﬁed in our chemical
proteomic experiments were endoplasmic reticulum (ER) or
mitochondria proteins (Figure 3C). One protein that stood out
was SLC25A20, also known as CACT, which is a multipass
integral membrane protein localized to the inner mitochondrial
membrane, where it transports long-chain acylcarnitines into
the mitochondrial matrix in exchange for free carnitine. These
acylcarnitines are then converted to fatty acyl CoAs by carnitine
palmitoyltransferase 2 (CPT-2) to provide fatty acid substrates
for β-oxidation.55−57
We identiﬁed SLC25A20 as a high-occupancy target of
IngMeb in all three tested cell types (Figure 3C,D), as well as a
high-occupancy target of IngDsx (Figure S2B), but not ingenol
(Figure S1D). In a separate study, we recently discovered a
selective and cell-active inhibitor of SLC25A20
EN968724936 (or EN936, compound 21 from reference 33;
Figure S4A)using a fully functionalized fragment (FFF)
platform for chemical proteomics.33 We conﬁrmed here that
EN936 blocks Ing-DAyne labeling of endogenous SLC25A20
(Figure S4B and Table S1) and, conversely, that IngMeb blocks
Figure 4. IngMeb and IngDsx block acylcarnitine metabolism and fatty acid oxidation in human cells. (A) IngMeb produces a concentration-
dependent increase in long-chain (>C14) acylcarnitine content in HSC-5 cells. Cells were treated with the indicated concentration of IngMeb for 3 h
prior to analysis of acylcarnitine content. (B) IngDsx (10, 100 μM 3 h) increases long-chain acylcarnitine content of HSC-5 cells. (C) IngMeb and
omeprazole (13, 100 μM each, 3 h), but not ingenol (2, 100 μM) or the pan-PKC agonist 12-O-tetradecanoylphorbal-13-acetate (TPA, 100 μM),
elevate long-chain acylcarnitines in HSC-5 cells. For A−C, data represent average values ± SD; n = 3 per group; *p < 0.05, **p < 0.01, ***p < 0.001,
and ****p < 0.0001 for compound- versus DMSO-treated groups (A−C) and ##p < 0.01 and ####p < 0.0001 for IngMeb vs IngDsx-treated groups
(B) or IngMeb vs omeprazole-treated groups (C) using unpaired Student’s t-tests. (D) IngMeb (1), omeprazole (13), and (E) IngDsx (100 μM
each) reduce exogenous fatty acid oxidation in HSC-5 cells. Plots depict eﬀect of compounds on spare respiratory capacity, deﬁned as the diﬀerence
between maximal respiration and basal respiration, normalized to vehicle treated cells. See Figure S5 for full oxygen consumption (OCR) plots. Data
represents averaged values ± SD; n = 5−6 per group; **p < 0.01 and ****p < 0.0001 for compound- versus DMSO-treated groups and #p < 0.05
and ##p < 0.01 for IngMeb vs IngDsx-treated groups using unpaired Student’s t-tests.
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SLC25A20 labeling with a FFF probe 12 (Figure S4C and
Table S1) that is structurally related to EN936 (Figure S4A).
These results indicate that IngMeb and EN936 may interact
with SLC25A20 at a common site.
We next tested whether IngMeb blocks SLC25A20 function
by treating HSC-5 cells with increasing concentrations of the
compound (1−200 μM 3 h) and then measuring cellular
acylcarnitine content by targeted LC−MS analysis. IngMeb
produced a strong concentration-dependent increase in long-
chain (C16, C18, C18:1) acylcarnitines in HSC-5 cells (Figure
4A). This pharmacological eﬀect was also observed with IngDsx
(Figure 4B), but not ingenol (Figure 4C). Signiﬁcantly higher
levels of C18 and C18:1 acylcarnitines were observed in HSC-5
cells treated with 100 μM IngDsx compared to 100 μM
IngMeb, consistent with the more complete competitive
blockade of Ing-DAyne labeling of SLC25A20 produced by
IngDsx compared to IngMb (Table S1). Importantly, the
general PKC activator TPA58 did not alter long-chain
acylcarnitines in HSC-5 cells (Figure 4C), and the PKC
inhibitor GF 109203X (GF)59 did not block acylcarnitine
elevations induced by IngMeb (Figure 4C). Lastly, IngMeb and
IngDsx did not alter the cellular amounts of short- or medium-
chain (<C14) acylcarnitines (Figures 4A and 4B), which are
thought to cross mitochondrial membranes by an SLC25A20-
independent mechanism, a hypothesis that is supported by the
selective elevations in long-chain acylcarnitines observed in the
serum of patients with SLC25A20 deﬁciency disorders.60,61
Previously, we reported that blockade of SLC25A20 activity
by EN936 resulted in impaired fatty acid oxidation (FAO) in
cells.33 We found that IngMeb and IngDsx also blocked FAO,
as HSC-5 cells treated with these compounds and palmitate (as
an exogenous fatty acid source) showed substantially reduced
oxygen consumption compared to control cells treated with
DMSO and palmitate (Figures 4D, 4E, and S5). IngDsx
produced signiﬁcantly more FAO inhibition compared to
IngMb, consistent with their respective eﬀects on SLC25A20-
dependent acylcarnitine content of HSC-5 cells. Tonazzi and
colleagues recently reported that omeprazole, an inhibitor of
K+/H+-ATPase used in the treatment of gastric secretions,
blocks SLC25A20-mediated transport of acylcarnitines across
proteoliposomes.62 We found that omeprazole substantially
blocked Ing-DAyne labeling of endogenous SLC25A20 in
HSC-5 cells (Figure S4D, Table S1), elevated long-chain
acylcarnitines (Figure 4C), and disrupted fatty acid oxidation
(Figure 4D). Our data, taken together, point to a highly
ligandable site on SLC25A20 where tool compounds (e.g.,
EN936) and drugs (IngMeb, IngDsx, and omeprazole)
converge to inactivate this transporter and impair mitochon-
drial fatty acid oxidation in cells.
We ﬁnally attempted to directly relate blockade of
SLC25A20 to the potential cytotoxic action of IngMb in
HeLa cells, but found that recombinantly expressing SLC25A20
(Figure S6A) did not shift the half-maximal cytotoxic eﬀect
(CC50) of the drug in this cell type (Figure S6B). We did note,
however, that expression of SLC25A20 reduced the eﬀect of
IngMeb on buildup of acylcarnitines (Figure S6C), further
validating SLC25A20 as a functionally perturbed target of
IngMeb. While these data might suggest that IngMeb
cytotoxicity occurs through primarily an SLC25A20-independ-
ent mechanism, we note that the very low potency of cell killing
in HeLa cells by IngMeb may not reﬂect the mode of
epiderimal cell death induced by this drug in vivo, where
SLC25A20 disruption could still play an important role.
■ CONCLUSION
The clinical eﬃcacy of IngMeb against AK is attributed to a
dual mechanism of action involving direct cytotoxicity and
immune-mediated clearance. Part of this activity appears to
reﬂect agonism of various PKC isoforms, leading to a
proinﬂammatory immune response as well as antiproliferative
eﬀects.27,28,63 The cell death induced by IngMeb at higher
concentrations similar to those achieved in topical treatments
of skin appears to reﬂect a distinct mechanism, bearing
resemblance to necrosis and being associated with a rise in
intracellular calcium as well as mitochondrial swelling and
rupture.26,31 To begin to understand the molecular interactions
of IngMeb that might contribute to the drug’s PKC-
independent activities, we designed and prepared a fully
functionalized ingenol-based probe containing photoreactive
and clickable groups and used this probe to map IngMeb
interactions in human cancer cells and keratinocytes by
quantitative MS-based proteomics. Several protein targets of
IngMeb were identiﬁed and veriﬁed in follow-up studies,
including the mitochondrial acylcarnitine transporter
SLC25A20, for which we found that IngMeb serves as an
inhibitor to block acylcarnitine uptake into the mitochondria
and subsequent mitochondrial FAO. Similar eﬀects were also
observed with the clinically relevant analogue IngDsx, but not
by the PKC agonist TPA.
The discovery that IngMeb and IngDsx block SLC25A20
could provide a molecular mechanism to explain, at least in
part, some of the mitochondrial defects observed in cells
treated with high concentrations of this drug. Indeed, global
genetic impairment of SLC25A20 alters energy metabolism and
results in an inherited lethal syndrome in humans.64
Determining the extent to which such altered mitochondrial
function contributes to the therapeutic mechanism of IngMeb
and IngDsx represents an important topic for future research.
The unchanged CC50 for IngMeb in HeLa cells that
overexpress SLC25A20 may indicate that the drug’s high-μM
cytotoxicity in cultured human cell lines occurs through distinct
targets. Still, this ﬁnding does not exclude a role for SLC25A20
inhibition in IngMeb-induced epidermal cell death in vivo,
where diverse fatty acid products contribute to keratinocyte
diﬀerentiation and function, and abnormalities in fatty acid
metabolism result in epidermal dysfunction.65 Further, given
that several high-occupancy targets were identiﬁed for IngMeb,
it is possible that functional perturbation of multiple targets
(i.e., polypharmacology66) contributes to IngMeb-mediated
mitochondrial and cytotoxic eﬀects.
More generally, our ﬁndings underscore that IngMeb and
IngDsx, at pharmacological concentrations likely achieved in
topical application of the drug for treatment of AK, engage
several proteins beyond the established interactions with PKCs.
Future studies aimed at determining which of these IngMeb-
binding proteins may contribute to cytotoxicity could include
genetic knockdown or knockout of individual proteins in
various IngMeb-sensitive cell types. That many of the detected
IngMeb−protein interactions appear to be of only moderate
(mid-μM) potency emphasizes an advantage of chemical
proteomic methods employing fully functionalized probes,
which can covalently trap lower aﬃnity small molecule−protein
binding events in cells. On the other hand, our inability to
verify PKCs as targets of IngMeb serves as a cautionary
reminder that photoreactive probes may also fail to detect
pharmacologically relevant targets of small molecules. This
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challenge may be addressed by placing the photoreactive group
at other locations on the bioactive drug, further emphasizing
the value of eﬃcient and ﬂexible synthetic routes for the varied
modiﬁcation of structurally complex natural products.
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